Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TCRX
Strong SellSinkerTScan Therapeutics, Inc. · Healthcare · United States · $51M · Avg Vol: $259K/d
7
StockRankGet insider-trade alerts
Q
11
V
43
M
23
P/E (TTM)
—
ROE
-95.8%
D/E
1.3x
Dividend %
—
COMPANY DESCRIPTION
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.5M | 21.0M | 2.8M | 10.3M | -8.6% | 7.1M | 5.5M | 4.7M | -32.4% |
| EPS | -1.09 | -1.36 | -1.14 | -1.00 | — | -0.90 | -0.85 | -0.73 | — |
| Shares | 61.1M | 47.8M | 56.6M | 56.9M | -6.8% | 63.5M | — | — | — |
| Debt | 86.0M | 92.4M | 97.4M | 94.1M | 3.1% | 90.9M | — | — | — |
| Equity | 99.4M | 150.9M | 241.0M | 123.1M | 7.4% | — | — | — | — |
| Op CF | -66.5M | -61.4M | -110.8M | -135.3M | — | -116.3M | — | — | — |
| Inv CF | -4.2M | -60.8M | -52.6M | 109.4M | — | — | — | — | — |
| Fin CF | 29.4M | 135.4M | 208.8M | -0.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-57.9%
SMA 50SMA 200
Close
$0.318
RSI (14)
8.7
52W High
$2.57
From 52W High
0.1%
SCORE BREAKDOWN
Quality
11
ROIC
-57.8%13.6
ROE
-95.8%10.1
GP/Assets
-38.6%2.0
Op. Margin
-2901.3%4.7
FCF/Assets
-54.6%6.1
Piotroski
29.5
Int. Cover
-43.7x12.4
D/E Ratio
1.32x9.8
Current Ratio
3.37x59.4
Value
43
P/E (TTM)
—N/A
EV/EBITDA
n/mN/A
P/FCF
n/mN/A
P/B
0.2x99.6
P/S
3.7x50.8
Div Yield
—N/A
Momentum
23
52W High %
12%1.4
RS 6M
-85%2.3
SMA 50/200
0.80x15.9
EPS Rev 4W
+18.0%94.0
EPS Rev 12W
—N/A
EPS Improve
+19%33.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$51M
P/E (Forward)
-0.5x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TCRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc.(you) | $51M | 7 | Strong Sell |
| ATYR | aTyr Pharma, Inc. | $53M | 7 | Strong Sell |
| MCRB | Seres Therapeutics, Inc. | $51M | 8 | Strong Sell |
| TIL | Instil Bio, Inc. | $51M | 9 | Strong Sell |
| CNTX | Context Therapeutics Inc. | $56M | 6 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| ELOX | Eloxx Pharmaceuticals, Inc. | $52M | 15 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%